To find out the efficacy and safety of topical fluorouracil (1%) cream in comparison to clobetasol propionate cream (0.05%) for the treatment of palmoplantar psoriasis
Not Applicable
- Conditions
- Health Condition 1: L408- Other psoriasis
- Registration Number
- CTRI/2021/09/036545
- Lead Sponsor
- Dr Prateek Chauhan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Inclusion criteria
Patients with Lesions covering more than 30% of palms/soles (palmoplantar psoriasis).
Patients age >18 years.
Patients who give their consent for the study.
Exclusion Criteria
Exclusion criteria
Patients of age <18 years
Patients with psoriatic lesions where systemic therapy is needed.
Pregnant and Breast feeding females.
Patients who had taken topical anti-psoriatic medication in 2 weeks or more before enrollment.
Patients who had taken systemic anti-psoriatic medication in 1 month or more before enrollment.
Patients who didnâ??t give their consent for the study or have not shown willingness for follow up.
Patients on oral steroids or immunosuppressing agents.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Morphology of lesions <br/ ><br>Duration of disease <br/ ><br>Size of lesion <br/ ><br>Infiltration <br/ ><br>Erythema <br/ ><br>Desquamation <br/ ><br>PASI score <br/ ><br>Timepoint: O weeks <br/ ><br>2 weeks <br/ ><br>4 weeks <br/ ><br>6 weeks <br/ ><br>8 weeks
- Secondary Outcome Measures
Name Time Method PASI SCORETimepoint: 0 weeks <br/ ><br>2 weeks <br/ ><br>4 weeks <br/ ><br>6 weeks <br/ ><br>8 weeks